May, 13 2022
Piombino Dese (PD), Italy – May 13, 2022 - In the coming weeks, Stevanato Group will be proactively involved in promoting its drug containment solutions and presenting its integrated portfolio of manufacturing services and automation equipment within the drug delivery systems space.
The Company will take part in three major shows in Europe and the U.S. – CPhI North America, Pharmapack Europe, and Interphex NY – during which visitors can meet our experts and discover the full breadth of Stevanato Group’s offering in terms of integrated capabilities: from high-quality drug containment solutions to device manufacturing, together with inspection systems and assembly equipment.
17 – 19 May 2022 - CPhI North America, Pennsylvania Convention Center, Philadelphia, booth no. 422: our team will be on hand for visitors and customers from North America to present the complete set of analytical services, assembly solutions, drug containment solutions, and contract manufacturing.
18 - 19 May 2022 - Pharmapack Europe, Paris Expo, booths no. B56 and B58: Stevanato Group will take part in the most relevant European trade show for the pharma packaging and drug delivery device industry with its portfolio of services in contract manufacturing and assembly. This year, the Company will be also pleased to present the recent collaboration with Owen Mumford for the innovative Aidaptus® auto-injector.
24 – 26 May 2022 – Interphex, Javits Center, NYC, booth no. 3204: Stevanato Group welcomes visitors and clients in New York with a live demo of a collaborative pilot assembly platform and presents its advanced inspection systems, to help pharma companies from the early stage up to the commercialization.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
This press release may include forward-looking statements. The words "expects", “planned”, "intended", “believe”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. In particular, the Company may determine not to conduct a registered initial public offering in the time frame that it currently expects or at all, due to a number of potential important factors, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments in the Company’s business, or unfavorable or regulatory developments. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.